Encompass Health Corp Hits 20-Day Low Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: Coinmarketcap
Encompass Health Corp's stock declined by 3.27%, hitting a 20-day low as market conditions weakened.
The Nasdaq-100 and S&P 500 showed slight gains, but Encompass Health's performance was negatively impacted by broader market trends.
This decline may raise concerns among investors about the company's resilience in a challenging market environment.
Analyst Views on EHC
Wall Street analysts forecast EHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EHC is 143.33 USD with a low forecast of 140.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 95.700
Low
140.00
Averages
143.33
High
150.00
Current: 95.700
Low
140.00
Averages
143.33
High
150.00
About EHC
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
